Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Cancer J. 2022 May-Jun;28(3):208–223. doi: 10.1097/PPO.0000000000000591

Figure 16.

Figure 16

The Heart Outcomes Prevention Evaluation-3 trial was a randomized, double-blinded, placebo-controlled primary cardiovascular disease prevention trial of statin therapy versus placebo conducted in 5,874 women and 6,831 men. After median 5.6 years of randomized treatment, cardiovascular disease was significantly reduced in men but not statistically significantly reduced in women. All-cause mortality was unaffected by statin therapy in both women and men (n=12,705) (38). CI = confidence interval